Cargando…
Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
Oxygen enriched air may increase oxygen pressure in brain tissue and have biochemical effects even in subjects without lung disease. Consistently, several studies demonstrated that normobaric oxygen treatment has clinical benefits in some neurological conditions. This study examined the efficacy of...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460750/ https://www.ncbi.nlm.nih.gov/pubmed/34556722 http://dx.doi.org/10.1038/s41598-021-98245-9 |
_version_ | 1784571821264207872 |
---|---|
author | Bloch, Yehudit Belmaker, R. H. Shvartzman, Pesach Romem, Pnina Bolotin, Arkady Bersudsky, Yuly Azab, Abed N. |
author_facet | Bloch, Yehudit Belmaker, R. H. Shvartzman, Pesach Romem, Pnina Bolotin, Arkady Bersudsky, Yuly Azab, Abed N. |
author_sort | Bloch, Yehudit |
collection | PubMed |
description | Oxygen enriched air may increase oxygen pressure in brain tissue and have biochemical effects even in subjects without lung disease. Consistently, several studies demonstrated that normobaric oxygen treatment has clinical benefits in some neurological conditions. This study examined the efficacy of normobaric oxygen treatment in subjects with depression. In a randomized, double-blind trial, 55 participants aged 18–65 years with mild to moderate depression (had a Hamilton Rating Scale for Depression [HRSD] score of ≥ 8) were recruited to the study from the Southern district in Israel. Participants underwent a psychiatric inclusion assessment at baseline and then were randomly assigned to either normobaric oxygen treatment of 35% fraction of inspired oxygen or 21% fraction of inspired oxygen (room air) through a nasal tube, for 4 weeks, during the night. Evaluations were performed at baseline, 2 and 4 weeks after commencement of study interventions, using the following tools: HRSD; Clinical Global Impression (CGI) questionnaire; World Health Organization-5 questionnaire for the estimation of Quality of Life (WHO-5-QOL); Sense of Coherence (SOC) 13-item questionnaire; and, Sheehan Disability Scale (SDS). A multivariate regression analysis showed that the mean ± standard deviation [SD] changes in the HRSD scores from baseline to week four were − 4.2 ± 0.3 points in the oxygen-treated group and − 0.7 ± 0.6 in the control group, for a between-group difference of 3.5 points (95% confidence interval [CI] − 5.95 to − 1.0; P = 0.007). Similarly, at week four there was a between-group difference of 0.71 points in the CGI score (95% CI − 1.00 to − 0.29; P = 0.001). On the other hand, the analysis revealed that there were no significant differences in WHO-5-QOL, SOC-13 or SDS scores between the groups. This study showed a significant beneficial effect of oxygen treatment on some symptoms of depression. Trial registration: NCT02149563 (29/05/2014). |
format | Online Article Text |
id | pubmed-8460750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-84607502021-09-27 Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial Bloch, Yehudit Belmaker, R. H. Shvartzman, Pesach Romem, Pnina Bolotin, Arkady Bersudsky, Yuly Azab, Abed N. Sci Rep Article Oxygen enriched air may increase oxygen pressure in brain tissue and have biochemical effects even in subjects without lung disease. Consistently, several studies demonstrated that normobaric oxygen treatment has clinical benefits in some neurological conditions. This study examined the efficacy of normobaric oxygen treatment in subjects with depression. In a randomized, double-blind trial, 55 participants aged 18–65 years with mild to moderate depression (had a Hamilton Rating Scale for Depression [HRSD] score of ≥ 8) were recruited to the study from the Southern district in Israel. Participants underwent a psychiatric inclusion assessment at baseline and then were randomly assigned to either normobaric oxygen treatment of 35% fraction of inspired oxygen or 21% fraction of inspired oxygen (room air) through a nasal tube, for 4 weeks, during the night. Evaluations were performed at baseline, 2 and 4 weeks after commencement of study interventions, using the following tools: HRSD; Clinical Global Impression (CGI) questionnaire; World Health Organization-5 questionnaire for the estimation of Quality of Life (WHO-5-QOL); Sense of Coherence (SOC) 13-item questionnaire; and, Sheehan Disability Scale (SDS). A multivariate regression analysis showed that the mean ± standard deviation [SD] changes in the HRSD scores from baseline to week four were − 4.2 ± 0.3 points in the oxygen-treated group and − 0.7 ± 0.6 in the control group, for a between-group difference of 3.5 points (95% confidence interval [CI] − 5.95 to − 1.0; P = 0.007). Similarly, at week four there was a between-group difference of 0.71 points in the CGI score (95% CI − 1.00 to − 0.29; P = 0.001). On the other hand, the analysis revealed that there were no significant differences in WHO-5-QOL, SOC-13 or SDS scores between the groups. This study showed a significant beneficial effect of oxygen treatment on some symptoms of depression. Trial registration: NCT02149563 (29/05/2014). Nature Publishing Group UK 2021-09-23 /pmc/articles/PMC8460750/ /pubmed/34556722 http://dx.doi.org/10.1038/s41598-021-98245-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Bloch, Yehudit Belmaker, R. H. Shvartzman, Pesach Romem, Pnina Bolotin, Arkady Bersudsky, Yuly Azab, Abed N. Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial |
title | Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial |
title_full | Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial |
title_fullStr | Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial |
title_full_unstemmed | Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial |
title_short | Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial |
title_sort | normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460750/ https://www.ncbi.nlm.nih.gov/pubmed/34556722 http://dx.doi.org/10.1038/s41598-021-98245-9 |
work_keys_str_mv | AT blochyehudit normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial AT belmakerrh normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial AT shvartzmanpesach normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial AT romempnina normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial AT bolotinarkady normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial AT bersudskyyuly normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial AT azababedn normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial |